Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: A meta-analysis

Inflammatory Bowel Diseases

Volumn 20, Issue 9, 2014, Pages 1562-1567

  Mardini, Houssam E ^a   Grigorian, Alla Y ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Meta analysis; Probiotics; Ulcerative colitis; VSL3

Indexed keywords

ACETYLSALICYLIC ACID; IMMUNOMODULATING AGENT; PLACEBO; VSL3; IMMUNOLOGIC FACTOR; PROBIOTIC AGENT;

ADJUVANT THERAPY; ARTICLE; BLOATING; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DRUG EFFICACY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS; ULCERATIVE COLITIS DISEASE ACTIVITY INDEX; COLITIS, ULCERATIVE; PATHOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

COLITIS, ULCERATIVE; HUMANS; IMMUNOLOGIC FACTORS; PROBIOTICS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84906283953     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000084     Document Type: Article

References (17)

1. Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology. 2014;146: 1554-1563.
2. Veerappan GR, Betteridge J, Young PE. Probiotics for the treatment of inflammatory bowel disease. Curr Gastroenterol Rep. 2012;14:324-333.
3. Meijer BJ, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol. 2011;45(suppl): S139-S144.
4. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014; 20:21-35.
5. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol. 1998;39: 237-238.
6. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269.
7. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Cochrane bias methods group; Cochrane statistical methods group. BMJ. 2011; 343:d5928.
8. Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. 2004;10:PI126-PI31.
9. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539-1546.
10. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1202-1209.
11. Ng SC, Plamondon S, Kamm MA, et al. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis. 2010; 16:1286-1298.
12. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-tomoderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105:2218-2227.
13. Mallon P, McKay D, Kirk S, et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007:CD005573.
14. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437-443.
15. Russo MW. How to review a meta-analysis. Gastroenterol Hepatol (N Y). 2007;3:637-642.
16. Talley NJ, Abreu MT, Achkar JP, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. American College of Gastroenterology IBD Task Force. Am J Gastroenterol. 2011; 106(suppl 1):S2-S25.
17. Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 2008;336:1413-1415.